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COST OF CARE FOR MEDICARE PATIENTS DIAGNOSED WITH 
METASTATIC BREAST CANCER WHO RECEIVED TRASTUZUMAB
Doan J1, Grifﬁ ths RI2, Lalla D1, Herbert R2, Brammer M1, Danese MD2
1Genentech, Inc., South San Francisco, CA, USA, 2Outcomes Insights, Inc, Newbury Park, CA, 
USA
OBJECTIVES: Trastuzumab (Herceptin) was approved in 1998 for treating patients 
with metastatic breast cancer. However, there is little information on the cost of care 
in these patients. The following abstract quantiﬁ es the costs for these patients.
METHODS: We used SEER-Medicare data to identify inpatient, outpatient, and total 
costs, in women diagnosed with metastatic breast cancer- Stage IV (S-IV) or Stage 0-III
with distant recurrence (S-DR) who received trastuzumab. An index date was deﬁ ned 
as either the date of diagnosis (S-IV) or of ﬁ rst distant recurrence (S-DR). Included 
patients were diagnosed in 2000–2002, and had their ﬁ rst claim for trastuzumab 
between their index date and December 31, 2005, the end of the observation period. 
Patients were divided into those who received trastuzumab as part of their ﬁ rst treat-
ment following their index date (Group A), and those who began trastuzumab after 
at least one course of chemotherapy (Group B). Monthly inpatient, outpatient, and 
total Medicare costs were calculated and adjusted to 2008 dollars using the Medicare 
component of the CPI. RESULTS: A total of 281 patients met the inclusion criteria, 
of whom 100 (36%) were diagnosed as stage IV at index (N  181 for stage 0-III with 
distant recurrence) and 191 patients received trastuzumab as part of initial treatment. 
For the group in general, the average total monthly cost was $6104– 29% due to 
inpatient costs ($1744). In bivariate analysis, the average cost for S-IV patients 
($6762) was signiﬁ cantly higher (p  0.03) than for S-DR patients ($5740), largely 
due to inpatient costs ($2253 versus $1463). The average monthly cost of care was 
signiﬁ cantly higher (p  0.004) in Group A ($6538) than Group B ($5168). These 
differences persisted in multivariate analyses. CONCLUSIONS: Medicare costs are
greater among women initially diagnosed with Stage IV breast cancer, compared to
those diagnosed with Stage 0-III disease who have a distant recurrence.
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ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/
INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT
OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
Greenberg D
Ben-Gurion University of the Negev, Beer-Sheva, Israel
OBJECTIVES: Metastatic renal cell carcinoma (mRCC) is highly resistant to chemo-
therapeutics, rendering limited anti-tumor effect. New treatments such as Sunitinib, 
Sorafenib, Bevacizumab/Interferon-alpha (INF-alpha), and Temsirolimus have been 
recently licensed for ﬁ rst-line treatment of patients with mRCC. We assessed the cost-
effectiveness of these therapies from the perspective of the Israeli health care payer. 
METHODS: We used a Markov model with a 10-year time horizon to simulate disease 
progression, survival, and cost outcomes for a hypothetical cohort of mRCC patients. 
Although no head-to- head trials comparing the new treatment modalities are avail-
able, most studies had compared the new therapies against INF-alpha, thus allowing
an indirect comparison of clinical efﬁ cacy. Utility weights were estimated from Suni-
tinib clinical trials using the EQ-5D. Drug and other health care costs were estimated 
from nationally published sources, and reported in 2008 New Israeli Shekels (NIS). 
Treatment effectiveness was measured in QALYs gained. Costs and beneﬁ ts were dis-
counted annually at 3%. We used a series of univariate and probabilistic sensitivity
analyses to test the robustness of our base-case ﬁ ndings. RESULTS: Sunitinib was the
most effective intervention and resulted in a gain of 0.27 QALYs compared with
Sorafenib and 0.08 QALYs gained compared with Bevacizumab/ INF-alpha or Temsi-
rolimus. The total discounted drug cost for treating mRCC patients was 277,184 NIS
for Sorafenib, 380,749 NIS for Temsirolimus, 343,712 NIS for Sunitinib, and 420,987 
NIS for Bevacizumab/INF-alpha. Treating patients with Sunitinib resulted in an ICER 
of 245,869 NIS (^$60,000) per QALY gained when compared with Sorafenib, and 
was the dominant intervention compared to the other treatment modalities. The model
results were robust to changes in a wide range of model parameters, including treat-
ment efﬁ cacy and follow-up treatment costs. CONCLUSIONS: Our model indicates 
that Sunitinib is a cost-saving alternative, when compared with Bevacizumab/INF-
alpha, and Temsirolimus and is within the accepted threshold for cost-effective inter-
ventions when compared with Sorafenib.
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COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST
SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE
IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL
CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE 
SYSTEM PERSPECTIVE
Teich V1, Fernandes RA1, Schiola A2
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OBJECTIVES: The objective of the study was to develop a cost-effectiveness analysis 
of sorafenib associated to BSC versus BSC alone in the second line treatment of 
advanced renal cell carcinoma (RCC) under the Brazilian public health care system 
perspective. METHODS: A Markov model was developed to project the lifetime costs
and outcomes associated with the disease progression of patients receiving sorafenib/
BSC or BSC alone. The cycle duration was three months and the corresponding transi-
tion probabilities were obtained from the TARGET study. The model considered three
health states: progression free survival, disease progression and death. The outcomes
were expressed as life years gained. Only direct medical costs were considered in the 
analysis, including drugs, physician visits, monitoring and treatment of adverse events. 
Unit costs for drugs were obtained from the Brazilian Health Prices Database (BPS) 
and procedure costs were extracted from the National Database of Ambulatory Costs 
(SIA/DATASUS). Costs and outcomes were discounted at an annual 5% discount rate. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: In a lifetime 
horizon, total costs per patient were R$48,285 for sorafenib/BSC and R$7,356 for 
BSC alone. Mean progression free survival for patients treated with both alternatives
were 2066 years and 1243 years, respectively, resulting in an incremental cost-effec-
tiveness ratio of R$49,751 (US$21,553) per life year gained. Varying the time horizon 
of the analysis increased the ICER for values above R$70,000 in time horizons below 
5 years. Varying the discount rate between 0% and 10% led to ICERs between 
R$46.589 and R$61,302, respectively. CONCLUSIONS: There’s no deﬁ ned threshold
for the accepted ICER in Brazil. Considering international standards, the incremental 
cost-effectiveness ratio would be around 3 times the Brazilian per capita Gross Domes-
tic Product. Therefore, sorafenib/BSC appears to be cost-effective in the management 
of advanced RCC.
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ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT
OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO
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OBJECTIVES: To analyze the cost-effectiveness of temozolomide in the treatment of 
newly diagnosed glioblastoma multiforme versus radiotherapy alone from the Mexican
health care perspective. METHODS: A cost-effectiveness analysis was performed 
based on a Markov model, with three health states: initial, disease progression and 
death. This model allowed us to compare the expected outcomes and costs associated
with temozolomide compared with radiotherapy alone for a synthetic cohort of 
patients aged q55 years over a 5-year period. The model cycles every six months and
continues until all patients die. The probabilities of transition between health states 
were obtained from the literature. Costs were expressed in 2008 US dollar. Outcome 
estimates included the incremental cost-effectiveness ratio (ICER) and cost per life-year
(LY) gained. Costs and health outcomes were discounted at 5%. Second-order Monte
Carlo simulations were undertaken in which values were randomly drawn from dis-
tributions of these parameters. RESULTS: The accumulated discounted effect is 1.03
LY per patient receiving temozolomide compared to 0.93 LY for radiotherapy alone. 
Total lifetime medical cost was US$31,698 for temozolomide vs US$30,715 for radio-
therapy alone. The incremental cost-effectiveness of temozolomide was US$983 per 
life year gained. There is a 70% probability that temozolomide is cost-effective at a 
US$10,000 per life-year saved threshold and a slightly more than 95% probability of 
being cost-effective at a US$18,000 per life-year saved threshold. CONCLUSIONS:
Results from these analyses suggest that in the Mexican setting, use of temozolomide 
in place of radiotherapy alone for treatment of glioblastoma multiforme is likely to
be cost saving. These conclusions are supported by the use of conservative assumptions 
and sensitivity analyses.
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COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE 
IN COLOMBIA IN 2007
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OBJECTIVES: To estimate the disease burden of human papillomavirus (HPV) related
cancers and preneoplastic lesions in Colombia, and the cost-effectiveness of introduc-
tion of HPV vaccine. METHODS: A full economic evaluation was done regarding
potential introduction of HPV vaccine. A Markov model that regards the natural 
history of disease was developed using software TreeAge Pro. The model allowed for
evaluating four different alternatives: 1) no intervention; 2) current Colombian screen-
ing program alone; 3) vaccination alone; and 4) combination of both. A systematic 
review was done to identify incidence, prevalence, mortality, and probability of pro-
gression/regression of cervical cancer, preneoplastic lesions, and vulva, anus, penis, 
and oropharynx cancer in Colombia. Other government and institutional databases 
were used to complement and validate these estimators. A similar procedure was per-
formed to identify the cost of attending these diseases, the frequency of use of related
services and the efﬁ cacy of vaccine. All costs were assessed in international dollars of 
2005 ($I). RESULTS: The burden of cervical cancer in 2007 was estimated in 54,884
DALYs, that were assumed attributable to HPV. Other HPV-related cancers accounted 
for 6346 YLL, and 1439 were considered attributable to HPV. At a cost per vaccinated 
woman (CpW) – three doses plus administrative costs- ranging from I$25 to I$75, 
strategy 2 was dominated by Strategies 3 and 4. Considering a life-time horizon, the 
incremental cost-effectiveness ratio of Intervention 4 over Intervention 3 was I$1,895, 
I$6,800 and I$11,000 at a CpW of I$150, I$300 and I$420, respectively. At CpW
lesser than I$75, the Strategy 3 was dominated. CONCLUSIONS: The sensibility
analysis showed that CpW is by far the most important variable for the model. At
CpW lesser than I$300, strategy 4 could be cost-effective. In that case, budgetary 
impact should be analyzed. In Colombia, the cost of current screening program is very
expensive, and alternative programs should be considered.
